Predictable marker for regression of barrett's esophagus by proton pump inhibitor treatment in Korea

Journal of Neurogastroenterology and Motility

Volumn 19, Issue 2, 2013, Pages 210-218

  Jo, Hyun Jin ^a   Lee, Hye Seung ^a   Kim, Nayoung ^a,b   Nam, Ryoung Hee ^a   Chang, Hyun ^a   Kim, Min Soo ^a   Kim, Sung Eun ^a   Oh, Jane C ^c   Lee, Dong Ho ^a,b   Jung, Hyun Chae ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Yonsei Plus Eye Center   (South Korea)

Author keywords

Barrett esophagus; Biologic markers; Regression

Indexed keywords

ESOMEPRAZOLE; KI 67 ANTIGEN; LANSOPRAZOLE; MUCIN 2; MUCIN 5AC; MUCIN 6; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CLINICAL ARTICLE; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; MALE; PHENOTYPE; PROTEIN EXPRESSION; REMISSION;

EID: 84876704927     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2013.19.2.210     Document Type: Article

References (43)

1. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-993.
2. Lee IS, Choi SC, Shim KN, et al. Prevalence of Barrett's esophagus remains low in the Korean population: nationwide cross-sectional prospective multicenter study. Dig Dis Sci 2010;55:1932-1939.
3. Milind R, Attwood SE. Natural history of Barrett's esophagus. World J Gastroenterol 2012;18:3483-3491.
4. Guardino JM, Khandwala F, Lopez R, Wachsberger DM, Richter JE, Falk GW. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006;101:2187-2193.
5. Wall CM, Charlett A, Caygill CP, et al. Are newly diagnosed columnar- lined oesophagus patients getting younger? Eur J Gastroenterol Hepatol 2009;21:1127-1131.
6. Falk GW. Barrett's esophagus - is it bad for your health? Am J Gastroenterol 2005;100:2622-2623.
7. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004;57:580-589.
8. de Bortoli N, Martinucci I, Piaggi P, et al. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year. Aliment Pharmacol Ther 2011;33:1019- 1027.
9. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett's esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol 2009;43:907-914.
10. Horwhat JD, Baroni D, Maydonovitch C, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007;102:497-506.
11. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-494.
12. Jo SY, Kim N, Lim JH, et al. Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. J Neurogastroenterol Motil 2013;19:61-69.
13. Amano Y, Kushiyama Y, Yuki T, et al. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy. J Gastroenterol Hepatol 2007;22:901-907.
14. Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-797.
15. Fujiwara Y, Takahashi S, Arakawa T, et al. A 2008 questionnairebased survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries. Digestion 2009;80:119-128.
16. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003;48:1537-1541.
17. Zaninotto G, Minnei F, Guirroli E, et al. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. Dig Liver Dis 2007;39:18-25.
18. Alcedo J, Ferrández A, Arenas J, et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus 2009;22:239-248.
19. Basu KK, Pick B, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 2004;16:171- 175.
20. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 2007; 39:581-587.
21. Abdalla M, Dhanekula R, Greenspan M, et al. Dysplasia detection rate of confirmatory EGD in nondysplastic Barrett's esophagus. Dis Esophagus Published Online First: 28 Sep 2012. Doi: 10.1111/ j.1442-2050.2012.01431.x.
22. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001;15:519-524.
23. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-1883.
24. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003;98: 2390-2394.
25. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92: 582-585.
26. Egger K, Meining A, Werner M, Höfler H, Classen M, Rösch T. Endoscopic measurement of Barrett's esophagus length is unreliable - a prospective comparative biopsy study. Z Gastroenterol 2004;42: 499-504.
27. Guda NM, Partington S, Vakil N. Inter- and intra-observer variability in the measurement of length at endoscopy: Implications for the measurement of Barrett's esophagus. Gastrointest Endosc 2004;59: 655-658.
28. Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink - is intestinal metaplasia dead? Am J Gastroenterol 2009;104: 2588-2594.
29. Coban S, Örmeci N, Savas B, et al. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and cyclooxygenase expressions using chromoendoscopical examination. Dis Esophagus 2013;26:189-196.
30. Ramires M, David L, Leitão D, Seixas M, Sansonetty F, Sobrinho-Simões M. Ki67 labelling index in gastric carcinomas. An immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas. J Pathol 1997; 182:62-67.
31. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
32. Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mössner J. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology 2000;47:962-966.
33. Türkmen IÇ, Bassüllü N, Uraz S, Yerdel MA, Memisoglu R, Bülbül Dogusoy G. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: Can they be useful in determination of the dysplasia? Turk Patoloji Derg 2012;28:251-258.
34. Phillips RW, Frierson HF Jr, Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-1447.
35. Colleypriest BJ, Palmer RM, Ward SG, Tosh D. Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends Mol Med 2009;15:313-322.
36. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004;17:1282-1288.
37. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008;295:G211-G218.
38. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 2004;122:61-69.
39. Boltin D, Halpern M, Levi Z, et al. Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers. World J Gastroenterol 2012;18:4597-4603.
40. Van Klinken BJ, Dekker J, Büller HA, Einerhand AW. Mucin gene structure and expression: protection vs. adhesion. Am J Physiol 1995; 269(5 Pt 1):G613-G627.
41. Ho SB, Roberton AM, Shekels LL, Lyftogt CT, Niehans GA, Toribara NW. Expression cloning of gastric mucin complementary DNA and localization of mucin gene expression. Gastroenterology 1995;109:735-747.
42. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, et al. Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol 2002;33:660-668.
43. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-1399.